<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font10 { font-size : 10; } .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font14 { font-size : 14; } .font15 { font-size : 15; } .font18 { font-size : 18; } .font19 { font-size : 19; } .font20 { font-size : 20; } .font21 { font-size : 21; } .font22 { font-size : 22; } .font25 { font-size : 25; } .font30 { font-size : 30; }</style>
 <body>
  <p>
   <span class="font30">[]. </span>
   <span class="font25">CMV </span>
   <span class="font25">EBV </span>
   <span class="font22">liver </span>
   <span class="font21">infection </span>
   <span class="font20">virus </span>
   <span class="font19">patients </span>
   <span class="font19">disease </span>
   <span class="font18">hepatitis </span>
   <span class="font15">viral </span>
   <span class="font15">immune </span>
   <span class="font15">cells </span>
   <span class="font14">acute </span>
   <span class="font14">associated </span>
   <span class="font14">antiviral </span>
   <span class="font14">transplant </span>
   <span class="font13">organ </span>
   <span class="font13">clinical </span>
   <span class="font13">primary </span>
   <span class="font13">viruses </span>
   <span class="font13">cytomegalovirus </span>
   <span class="font13">recipients </span>
   <span class="font13">treatment </span>
   <span class="font13">severe </span>
   <span class="font13">chronic </span>
   <span class="font13">risk </span>
   <span class="font13">Epstein-Barr </span>
   <span class="font13">cell </span>
   <span class="font13">{border-style </span>
   <span class="font12">immunocompetent </span>
   <span class="font12">Liver </span>
   <span class="font12">px;} </span>
   <span class="font12">therapy </span>
   <span class="font12">#ffffff;} </span>
   <span class="font12">herpes </span>
   <span class="font12">human </span>
   <span class="font12">increased </span>
   <span class="font12">mild </span>
   <span class="font12">reactivation </span>
   <span class="font12">virus, </span>
   <span class="font12">DNA </span>
   <span class="font12">PTLD </span>
   <span class="font12">infections </span>
   <span class="font12">cause </span>
   <span class="font12">immunocompromised </span>
   <span class="font12">latent </span>
   <span class="font12">transplantation </span>
   <span class="font11">diagnosis </span>
   <span class="font11">infection, </span>
   <span class="font11">lymphoproliferative </span>
   <span class="font11">EBV-specific </span>
   <span class="font11">HSV </span>
   <span class="font11">development </span>
   <span class="font11">ganciclovir </span>
   <span class="font11">patients, </span>
   <span class="font11">common </span>
   <span class="font11">hepatitis, </span>
   <span class="font11">immunity </span>
   <span class="font11">include </span>
   <span class="font11">inflammatory </span>
   <span class="font11">replication </span>
   <span class="font11">review </span>
   <span class="font11">solid </span>
   <span class="font11">usually </span>
   <span class="font11">prophylaxis </span>
   <span class="font11">Infection </span>
   <span class="font11">allograft </span>
   <span class="font11">cells, </span>
   <span class="font11">early </span>
   <span class="font11">failure </span>
   <span class="font11">fulminant </span>
   <span class="font11">hepatotropic </span>
   <span class="font11">including </span>
   <span class="font11">innate </span>
   <span class="font11">lead </span>
   <span class="font11">manifestations </span>
   <span class="font11">mortality </span>
   <span class="font11">role </span>
   <span class="font11">CTLs </span>
   <span class="font11">EBV-associated </span>
   <span class="font11">HCV </span>
   <span class="font11">antibodies </span>
   <span class="font11">blood </span>
   <span class="font11">cases </span>
   <span class="font11">classic </span>
   <span class="font11">considered </span>
   <span class="font11">control </span>
   <span class="font11">detected </span>
   <span class="font11">develop </span>
   <span class="font11">effective </span>
   <span class="font11">expression </span>
   <span class="font11">hepatic </span>
   <span class="font11">observed </span>
   <span class="font11">oral </span>
   <span class="font11">preemptive </span>
   <span class="font11">proteins </span>
   <span class="font11">px; </span>
   <span class="font11">simplex </span>
   <span class="font11">{font-family </span>
   <span class="font11">Infect </span>
   <span class="font11">Rare </span>
   <span class="font11">[], </span>
   <span class="font11">active </span>
   <span class="font11">adaptive </span>
   <span class="font11">autoimmune </span>
   <span class="font11">complications </span>
   <span class="font11">detection </span>
   <span class="font11">disease. </span>
   <span class="font11">elevation </span>
   <span class="font11">following </span>
   <span class="font11">font-size </span>
   <span class="font11">genome </span>
   <span class="font11">higher </span>
   <span class="font11">incidence </span>
   <span class="font11">individuals </span>
   <span class="font11">injury </span>
   <span class="font11">latency </span>
   <span class="font11">lytic </span>
   <span class="font11">majority </span>
   <span class="font11">necrosis </span>
   <span class="font11">occur </span>
   <span class="font11">response </span>
   <span class="font11">responses </span>
   <span class="font11">syndrome </span>
   <span class="font11">transient </span>
   <span class="font11">transplantation. </span>
   <span class="font11">treated </span>
   <span class="font11">use </span>
   <span class="font10">Dis </span>
   <span class="font10">Early </span>
   <span class="font10">Ganciclovir </span>
   <span class="font10">However, </span>
   <span class="font10">Patients </span>
   <span class="font10">T-cell </span>
   <span class="font10">Virus </span>
   <span class="font10">acyclovir </span>
   <span class="font10">adults </span>
   <span class="font10">aminotransferases </span>
   <span class="font10">asymptomatic </span>
   <span class="font10">bile </span>
   <span class="font10">biopsy </span>
   <span class="font10">cases, </span>
   <span class="font10">donor </span>
   <span class="font10">double; </span>
   <span class="font10">duct </span>
   <span class="font10">fever </span>
   <span class="font10">host </span>
   <span class="font10">hosts </span>
   <span class="font10">infected </span>
   <span class="font10">infection. </span>
   <span class="font10">infectious </span>
   <span class="font10">late </span>
   <span class="font10">levels </span>
   <span class="font10">post-transplant </span>
   <span class="font10">present </span>
   <span class="font10">presentation </span>
   <span class="font10">prevention </span>
   <span class="font10">promote </span>
   <span class="font10">ranges </span>
   <span class="font10">reduction </span>
   <span class="font10">report </span>
   <span class="font10">reported </span>
   <span class="font10">site </span>
   <span class="font10">suggested </span>
   <span class="font10">transplantation, </span>
   <span class="font10">.). </span>
   <span class="font10">B-cell </span>
   <span class="font10">D/R− </span>
   <span class="font10">EBV-infected </span>
   <span class="font10">Epstein–Barr </span>
   <span class="font10">IL-, </span>
   <span class="font10">PCR </span>
   <span class="font10">Transplant./j.-...x </span>
   <span class="font10">Treatment </span>
   <span class="font10">Valganciclovir </span>
   <span class="font10">Viral </span>
   <span class="font10">ability </span>
   <span class="font10">affected </span>
   <span class="font10">agents </span>
   <span class="font10">antigen </span>
   <span class="font10">antigens </span>
   <span class="font10">based </span>
   <span class="font10">border-color </span>
   <span class="font10">border-width </span>
   <span class="font10">bowel </span>
   <span class="font10">case </span>
   <span class="font10">cellular </span>
   <span class="font10">colitis </span>
   <span class="font10">course </span>
   <span class="font10">damage </span>
   <span class="font10">different </span>
   <span class="font10">directed </span>
   <span class="font10">disease, </span>
   <span class="font10">diseases </span>
   <span class="font10">end </span>
   <span class="font10">fatal </span>
   <span class="font10">gastrointestinal </span>
   <span class="font10">healthy </span>
   <span class="font10">hepatitis. </span>
   <span class="font10">hepatocytes </span>
   <span class="font10">high </span>
   <span class="font10">immune-competent </span>
   <span class="font10">immunity, </span>
   <span class="font10">inclusions </span>
   <span class="font10">infections, </span>
   <span class="font10">inhibits </span>
   <span class="font10">involvement </span>
   <span class="font10">lymphocytes </span>
   <span class="font10">memory </span>
   <span class="font10">patients. </span>
   <span class="font10">possible </span>
   <span class="font10">promotes </span>
   <span class="font10">range </span>
   <span class="font10">rapid </span>
   <span class="font10">recipients, </span>
   <span class="font10">rejection </span>
   <span class="font10">small </span>
   <span class="font10">solid; </span>
   <span class="font10">strategies </span>
   <span class="font10">therapy. </span>
   <span class="font10">transplantation: </span>
   <span class="font10">type </span>
   <span class="font10">used </span>
   <span class="font10">valganciclovir </span>
   <span class="font10">varicella </span>
   <span class="font10">viruses, </span>
   <span class="font10">{font-style </span>
   <span class="font10">{font-weight </span>
   <span class="font10">(blood </span>
   <span class="font10">CD() </span>
   <span class="font10">Chronic </span>
   <span class="font10">Clinical </span>
   <span class="font10">Dis./ </span>
   <span class="font10">Gastroenterol </span>
   <span class="font10">HBV </span>
   <span class="font10">Hepatitis </span>
   <span class="font10">Herpes </span>
   <span class="font10">IFN-γ </span>
   <span class="font10">IgM </span>
   <span class="font10">Med </span>
   <span class="font10">Medicine, </span>
   <span class="font10">Primary </span>
   <span class="font10">TLR </span>
   <span class="font10">TNF-α </span>
   <span class="font10">Table </span>
   <span class="font10">affecting </span>
   <span class="font10">analysis </span>
   <span class="font10">apoptosis </span>
   <span class="font10">bold </span>
   <span class="font10">cell-mediated </span>
   <span class="font10">cells. </span>
   <span class="font10">central </span>
   <span class="font10">combination </span>
   <span class="font10">commonly </span>
   <span class="font10">compared </span>
   <span class="font10">courier; </span>
   <span class="font10">cycle </span>
   <span class="font10">degree </span>
   <span class="font10">described </span>
   <span class="font10">direct </span>
   <span class="font10">disorder </span>
   <span class="font10">does </span>
   <span class="font10">drugs </span>
   <span class="font10">effects </span>
   <span class="font10">elevated </span>
   <span class="font10">em; </span>
   <span class="font10">establish </span>
   <span class="font10">expressed </span>
   <span class="font10">form </span>
   <span class="font10">gene </span>
   <span class="font10">genes </span>
   <span class="font10">graft </span>
   <span class="font10">granulomatous </span>
   <span class="font10">hemorrhagic </span>
   <span class="font10">hepatitis: </span>
   <span class="font10">however, </span>
   <span class="font10">important </span>
   <span class="font10">increase </span>
   <span class="font10">indistinguishable </span>
   <span class="font10">induced </span>
   <span class="font10">intranuclear </span>
   <span class="font10">involved </span>
   <span class="font10">lesions </span>
   <span class="font10">life-threatening </span>
   <span class="font10">lifelong </span>
   <span class="font10">loss </span>
   <span class="font10">low </span>
   <span class="font10">lower </span>
   <span class="font10">lymphoma, </span>
   <span class="font10">major </span>
   <span class="font10">monitored </span>
   <span class="font10">mononucleosis </span>
   <span class="font10">months </span>
   <span class="font10">nervous </span>
   <span class="font10">occurs </span>
   <span class="font10">outcome </span>
   <span class="font10">outcomes </span>
   <span class="font10">phases </span>
   <span class="font10">play </span>
   <span class="font10">potential </span>
   <span class="font10">prophylaxis, </span>
   <span class="font10">pt;} </span>
   <span class="font10">reaction </span>
   <span class="font10">received </span>
   <span class="font10">recent </span>
   <span class="font10">recently </span>
   <span class="font10">recommended </span>
   <span class="font10">rejection, </span>
   <span class="font10">rejection. </span>
   <span class="font10">resulting </span>
   <span class="font10">retinitis, </span>
   <span class="font10">specific </span>
   <span class="font10">spectrum </span>
   <span class="font10">symptomatic </span>
   <span class="font10">therapy, </span>
   <span class="font10">thrombocytopenia, </span>
   <span class="font10">tissue) </span>
   <span class="font10">tract </span>
   <span class="font10">viremia </span>
   <span class="font10">virus-specific </span>
   <span class="font10">vs. </span>
   <span class="font10">young </span>
   <span class="font10">zoster </span>
  </p>
 </body>
</html>
